Project Grant R41DK146563
- This federal Project Grant award, in the amount of $531,999.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award is supporting research focused on understanding the role of alternative splicing in the proximal tubules of the kidney and its relationship to the progression of diabetic kidney disease. The research will investigate how diabetes...
- This Project Grant award of $830,500.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program) supports research investigating the role of glycosphingolipids in kidney disease associated with diabetes and obesity. The key objectives are to: Test whether inhibiting glucosylceramide synthesis in podocytes, renal tubules, or the immune system can prevent progression of kidney disease in mouse...
- This federal Project Grant award of $304,993 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Immunowork LLC, located in Monrovia, CA. The award supports a research project to quantify peripheral blood antigen-specific memory B cells as a new biomarker in patients with PLA2R-associated membranous nephropathy, a common form of nephrotic syndrome. The goal...
- This $128,286 Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research into the mechanisms of renal lipotoxicity and its contribution to the development of chronic kidney disease (CKD). The principal investigator will investigate the protective role of the FAF2 gene knockout in mitigating palmitate-induced lipotoxicity in...
- This Project Grant award of $277,089, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to improve understanding of the genetic drivers of nephrotic syndrome (NS) in order to guide clinical management and develop targeted therapies. The research, conducted by The Children's Hospital Corporation (dba Boston Children's Hospital), will investigate the...
- This federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $306,867 award to Dupage Medical Technology Inc. supports the development of a new drug to treat ischemia-reperfusion injury associated with kidney transplantation. The project aims to develop a therapy that can reduce inflammation and thrombosis without causing excessive...
- This federal Project Grant award of $168,886 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research to elucidate the role of NAD+ and PARP1 in nephron endowment and kidney development. The 5-year project, awarded on May 1, 2025 with a completion date of January 31, 2030, will be conducted by the University of Texas Southwestern Medical Center. The...
- This federal Project Grant award of $176,244 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to the University of California, San Francisco supports a 5-year research and training plan focused on the mechanisms underlying ciliary kidney diseases. The grant recipient, Dr. Gabriel Loeb, will investigate whether the transcription factor GLIS3 is regulated by the polycystin proteins and acts downstream of them to prevent kidney cyst formation. This work aims...
- This $400,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to understand the earliest events in podocyte injury in collagen IV nephropathies. The goal is to investigate how processing of mutant collagen IV proteins injures podocytes at early stages, leading to chronic kidney disease and renal failure. The research uses...
- This federal Project Grant award of $3,010,432 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding research to develop mitoprotective therapies for the treatment of acute kidney injury (AKI). The key objectives of this research are to characterize a novel mitochondrial protein target, phospholipid scramblase 3 (PLSCR3), and evaluate pharmacological activators...
This federal Project Grant award of $305,786 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Cypress Biopharma, Inc. The grant supports research to develop a novel non-immunosuppressive therapy for childhood nephrotic syndrome (NS). The project aims to leverage the highly active metabolite of pioglitazone as a scaffold to design a drug that can preferentially accumulate in the kidneys, potentially improving efficacy while reducing serious side effects associated with current NS treatments. Key activities include characterizing the lead metabolite and its stereoisomers to understand their binding, functional differences, and downstream effects in NS. The award has a project period from Sep 2025 to Aug 2026.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $305.8k | 9/10/25 |